Vaccine Research

Company to launch cancer-vaccine research sub: BN ImmunoTherapeutics

Published in Women's Health Weekly, January 20th, 2005

Bavarian Nordic, A/S, announced that it is establishing BN ImmunoTherapeutics, Inc., a cancer vaccine-research subsidiary in the Palo Alto area of California, to initially focus on the research and development of cancer vaccines against breast, prostate, and colon cancers.

Best known for its state-of-the-art, third-generation smallpox vaccine, Bavarian Nordic will utilize its patented MVA-BN vaccine vector in the development of these cancer vaccine-development programs.

"The combination of new and promising data from our earlier cancer projects combined with the strong safety profile of our MVA-BN technology has led us to expand our research in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-01-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry